BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26051101)

  • 1. Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index.
    de Mendonça-Louzeiro MR; Annichino-Bizzacchi JM; Benetti-Pinto CL
    Fertil Steril; 2015 Aug; 104(2):467-73. PubMed ID: 26051101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index.
    de Mendonça-Louzeiro MR; Annichino-Bizzacchi JM; Magna LA; Quaino SK; Benetti-Pinto CL
    Fertil Steril; 2013 May; 99(6):1786-90. PubMed ID: 23415973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body fat composition and distribution in women with polycystic ovary syndrome.
    Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
    Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
    Güldaş M; Altinkaya SÖ; Nergiz S; Demircan-Sezer S; Yüksel H
    Gynecol Endocrinol; 2015 Jul; 31(7):536-9. PubMed ID: 26220768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome.
    Godtfredsen ACM; Sidelmann JJ; Gram JB; Andersen M; Glintborg D
    Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1078-1084. PubMed ID: 32048272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls.
    Glintborg D; Andersen M; Hagen C; Frystyk J; Hulstrøm V; Flyvbjerg A; Hermann AP
    Eur J Endocrinol; 2006 Aug; 155(2):337-45. PubMed ID: 16868149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of regional fat mass measurement by whole body DXA scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls.
    Glintborg D; Petersen MH; Ravn P; Hermann AP; Andersen M
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1235-1243. PubMed ID: 27529295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome.
    Barber TM; Golding SJ; Alvey C; Wass JA; Karpe F; Franks S; McCarthy MI
    J Clin Endocrinol Metab; 2008 Mar; 93(3):999-1004. PubMed ID: 18089693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome.
    Chen L; Xu WM; Zhang D
    Fertil Steril; 2014 Oct; 102(4):1167-1174.e4. PubMed ID: 25064406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome.
    Ezeh U; Pall M; Mathur R; Azziz R
    Hum Reprod; 2014 Jul; 29(7):1508-17. PubMed ID: 24813197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome.
    Morrison SA; Goss AM; Azziz R; Raju DA; Gower BA
    Hum Reprod; 2017 Jan; 32(1):185-192. PubMed ID: 27827322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.
    Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
    Graff SK; Mário FM; Alves BC; Spritzer PM
    Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
    Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
    Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasonographic extended-view technique for evaluation of abdominal fat distribution in lean women with polycystic ovary syndrome.
    Battaglia C; Battaglia B; Mancini F; Paradisi R; Fabbri R; Venturoli S
    Acta Obstet Gynecol Scand; 2011 Jun; 90(6):600-8. PubMed ID: 21401530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
    Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
    Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome.
    Faloia E; Canibus P; Gatti C; Frezza F; Santangelo M; Garrapa GG; Boscaro M
    J Endocrinol Invest; 2004 May; 27(5):424-9. PubMed ID: 15279073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
    Atiomo WU; Fox R; Condon JE; Shaw S; Friend J; Prentice AG; Wilkin TJ
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):487-92. PubMed ID: 10762292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.